immunity News and Research

RSS

Researchers reach new milestone in the development of effective malaria vaccine

Sanaria PfSPZ-CVac" is a live vaccine consisting of infectious Plasmodium falciparum (Pf) malaria parasites that are injected into the subject at the same time as they receive an antimalarial drug.

5 May 2021

Robust passive and active immunity found in infants born to COVID-19 positive mothers

A new study provides evidence that babies born to mothers who were COVID-19 positive two or more months before delivery are protected by maternal antibodies, besides mounting a robust immune response in case they contract the infection in the perinatal period.

5 May 2021

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Mechano-immunological response to SARS-CoV-2

In a recent study, researchers demonstrated a human organ-on-a-chip (Organ Chip) microfluidic model of the lung alveolus (Alveolus Chip) - that recapitulates the human alveolar-capillary interface with an air-liquid interface (ALI) and vascular fluid flow to understand the local triggers in the lung in vitro.

5 May 2021

Certain parts of the innate immune response can be trained in response to HIV

Immunity often calls to mind the adaptive immune response, made up of antibodies and T cells that learn to fight specific pathogens after infection or vaccination.

5 May 2021

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Researchers in the United States have shown that the Pfizer/BioNTech and Moderna messenger RNA (mRNA) vaccines are effective at generating T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Study identifies novel combination therapy to help patients with advanced lung cancer

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer.

5 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

Study investigates how Brd4 influences diet-induced obesity

A new study, published in JCI Insight, looks at how Brd4, a regulator of the innate immune response, influences diet-induced obesity.

4 May 2021

Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults

After spending much of the past year tending to elderly patients, doctors are seeing a clear demographic shift: young and middle-aged adults make up a growing share of the patients in covid-19 hospital wards.

4 May 2021

New computational tool helps screen molecules for their potential COVID-fighting properties

A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-CoV-2.

4 May 2021

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

Researchers in the United States and India have conducted a study demonstrating the real-world effectiveness of a single dose of Johnson & Johnson’s Ad26.COV2.S vaccine at preventing infection with severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

3 May 2021

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient’s age and disease severity.

3 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Discovery opens new avenues for developing antibody-based therapies for malaria

WEHI researchers have identified how natural human antibodies can block malaria parasites from entering red blood cells, potentially indicating how new protective therapies could be developed against this globally significant disease.

3 May 2021

As vaccine demand slows, political differences go on display in California Counties

Demand for Covid vaccines is slowing across most of California, but as traffic at vaccination sites eases, the vaccination rates across the state are showing wide disparities.

3 May 2021

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

immunity News and Research

Researchers reach new milestone in the development of effective malaria vaccine

Robust passive and active immunity found in infants born to COVID-19 positive mothers

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Mechano-immunological response to SARS-CoV-2

Certain parts of the innate immune response can be trained in response to HIV

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Study identifies novel combination therapy to help patients with advanced lung cancer

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Study investigates how Brd4 influences diet-induced obesity

Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults

New computational tool helps screen molecules for their potential COVID-fighting properties

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Discovery opens new avenues for developing antibody-based therapies for malaria

As vaccine demand slows, political differences go on display in California Counties

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News